Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -80.5% | -39.5% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 3.7 | 2.9 |
Pr/Book | 1.9 |
Latest | F'cast | |
---|---|---|
Revenue | 13.2% | 28.4% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-19 | 0.01 | (18.62) | (12.54)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-20 | 9.43 | (23.46) | (12.54)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 25.16 | (30.34) | (14.48)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 27.20 | (30.90) | (14.48)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-23 | 30.80 | (24.50) | (7.00)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-24 | 39.56 | (15.63) | (3.75)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-25 | 53.57 | (4.33) | (0.83)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-26 | 70.00 | 4.00 | 1.42p | 22.0 | n/a | n/a | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Creo and Intuitive amend collaboration agreement | 02-Jul-2024 | 07:00 | RNS |
Result of AGM | 26-Jun-2024 | 10:51 | RNS |
AGM Statement and Directorate Succession Planning | 26-Jun-2024 | 07:00 | RNS |
Creo Medical reports year of solid progress | 26-Jun-2024 | ShareCast |
Creo device used in 'groundbreaking' lung cancer... | 01-Mar-2024 | ShareCast |
Creo Medical FY revenues up double digits | 07-Feb-2024 | ShareCast |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 30.75p |
Change Today | -0.50p |
% Change | -1.60 % |
52 Week High | 48.10 |
52 Week Low | 29.75 |
Volume | 430,670 |
Shares Issued | 361.48m |
Market Cap | £111.15m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:21 | 3,217 @ 30.96p |
16:18 | 1,000 @ 30.68p |
15:54 | 224 @ 30.65p |
15:52 | 2,403 @ 30.96p |
15:37 | 9,869 @ 30.97p |
CEO | Craig Jonathan Gulliford |
CFO | Richard John Rees |
You are here: research